We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
A new world is possible. Let's not go back to what wasn't working anyway.
Add this topic to your myFT Digest for news straight to your inbox
The acquisition is a sign of the French pharma group’s determination to get back on the podium
French pharma group tries to catch up with rivals that used the technology to create Covid vaccines
French group still aims for its Covid-19 jab to be approved by year end
French group to open a ‘dedicated mRNA centre of excellence’ after falling behind in Covid-19 jab race
Britain’s pension regulator says French drugmaker began talks after threat of enforcement action
UK group and France’s Sanofi release trial data of Covid jab showing strong immune response
French group has fallen behind newcomers despite being one of the biggest jab makers in world
New vaccine producers and mRNA technology are shaking up the market
GlaxoSmithKline, Merck and Sanofi are left playing catch-up to upstarts with new technology
French vaccine maker aims to get a Covid-19 shot to market by the fourth quarter
Deal is latest in string of acquisitions that have given drugmaker access to new technologies
French group also weighs possibility of manufacturing rival Covid-19 vaccines
European partnership hit by dosage issues while Canberra project is derailed by false positive HIV tests
If vaccination becomes a habit, strong demand would be more than a blip
As the French group tries to reduce dependence on some drugs, bolt-on deals make sense
Chief Paul Hudson’s strategy aims to shift focus to therapies for rarer diseases
Governments must resist the urge towards protectionism
Washington will pay up to $2.1bn to speed up development and secure an initial 100m doses
Both companies stand to benefit from the spotlight on immunisation
Advance purchase agreement depends on clinical trials starting in September
Group’s €610m investment comes as race to develop treatments becomes increasingly political
Stock sale by French drugmaker will be used to develop new drugs and to fuel acquisitions
Extra firepower will expand French pharmaceutical company’s options
Chief executive Paul Hudson says proceeds will go to scientific research and potentially acquisitions
International Edition
